Role of Surgery Could Change Following Durvalumab Approval for Stage III NSCLC
Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.
Source: OncLive